Drug Trial Radar · NCT07821944
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Nov 26, 2027
Study completion Nov 26, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.
Conditions
- Hyperlipidemia
- Hypercholesterolemia
Interventions
Enlicitide DecanoateDrug
Oral administration
PlaceboOther
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24Time frame: Baseline and Week 24
- Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 32 Weeks
- Number of Participants who Discontinue Study Drug Due to One or More AEsTime frame: Up to approximately 24 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
KLES Prabhakar Kore Hospital & Medical Research Centre [M] ( Site 1004)
Belagavi, Karnataka, India · Recruiting
Sir Ganga Ram Hospital ( Site 1001)
New Delhi, National Capital Territory of Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.